Tivozanib is primarily used in the treatment of advanced renal cell carcinoma (RCC), a type of kidney cancer. It works by inhibiting vascular endothelial growth factor receptors (VEGFRs), which are crucial for the growth and spread of cancer cells by promoting angiogenesis, the formation of new blood vessels that supply tumors with nutrients and oxygen. By blocking these receptors, Tivozanib effectively starves the tumor, slowing its growth and progression. It is often prescribed for patients who have not responded well to other treatments or as a second-line therapy. The drug is administered orally, offering a convenient treatment option for patients. Its targeted mechanism of action helps minimize damage to healthy cells, reducing the severity of side effects compared to traditional chemotherapy. Clinical trials have shown that Tivozanib can improve progression-free survival in patients with advanced RCC, making it a valuable option in oncology.